<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Vyome Holdings, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/vyome-holdings-inc</link>
    <description>Latest news and press releases for Vyome Holdings, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 06 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/vyome-holdings-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d75a6d51cc36e475337efc.webp</url>
      <title>Vyome Holdings, Inc.</title>
      <link>https://6ix.com/company/vyome-holdings-inc</link>
    </image>
    <item>
      <title>Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-for-treatment-of-mfw-at-aacr-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-for-treatment-of-mfw-at-aacr-2026</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 06, 2026--Vyome Holdings, Inc. (&quot;Vyome&quot;) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (&quot;MFW&quot;) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego.</description>
    </item>
    <item>
      <title>Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-phase</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-phase</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive</description>
    </item>
    <item>
      <title>Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-dollar3b-potential-market-opportunity</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-dollar3b-potential-market-opportunity</guid>
      <pubDate>Wed, 18 Feb 2026 14:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., February 18, 2026--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity</description>
    </item>
    <item>
      <title>Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-files-for-vt-1953-orphan-drug-status-furthers-strategic-focus-on-vt-1953-program-over-the-next-6-months</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-files-for-vt-1953-orphan-drug-status-furthers-strategic-focus-on-vt-1953-program-over-the-next-6-months</guid>
      <pubDate>Wed, 11 Feb 2026 05:00:00 GMT</pubDate>
      <description>Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&amp;D tax benefits, and PDUFA fee waiver of approximately $3M</description>
    </item>
    <item>
      <title>Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-successfully-capitalizes-all-vt-1953-funding-requirements-for-initial-phase-3-results</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-successfully-capitalizes-all-vt-1953-funding-requirements-for-initial-phase-3-results</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product CAMBRIDGE,</description>
    </item>
    <item>
      <title>Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-subsidiary-livechain-lich-to-acquire-senior-secured-note-in-humanyze-an-mit-incubated-company-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-subsidiary-livechain-lich-to-acquire-senior-secured-note-in-humanyze-an-mit-incubated-company-1</guid>
      <pubDate>Mon, 22 Dec 2025 13:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., December 22, 2025--LICH LOI with Remus</description>
    </item>
    <item>
      <title>Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-reports-positive-final-phase-2-results-for-vt-1953-plans-to-advance-into-pivotal-study-for-fda-approval</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-reports-positive-final-phase-2-results-for-vt-1953-plans-to-advance-into-pivotal-study-for-fda-approval</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound</description>
    </item>
    <item>
      <title>Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-appoints-renowned-medical-oncologist-dr-aditya-bardia-as-senior-medical-advisor-to-guide-the-development-of-mfw-program</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-appoints-renowned-medical-oncologist-dr-aditya-bardia-as-senior-medical-advisor-to-guide-the-development-of-mfw-program</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc.</description>
    </item>
    <item>
      <title>Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-announces-transformational-first-quarter-following-nasdaq-listing</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-announces-transformational-first-quarter-following-nasdaq-listing</guid>
      <pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
      <description>(Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure Delivered encouraging interim Phase 2</description>
    </item>
    <item>
      <title>Vyome Holdings Announces Results of Annual Shareholder Meeting</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-announces-results-of-annual-shareholder-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-announces-results-of-annual-shareholder-meeting</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>All 3 Class I directors, formerly at MIT, are re-elected to the board until the 2028 annual meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc.</description>
    </item>
    <item>
      <title>Vyome Holdings Acquires MIT AI Spinout Oculo Health</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-acquires-mit-ai-spinout-oculo-health</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-acquires-mit-ai-spinout-oculo-health</guid>
      <pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
      <description>Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets</description>
    </item>
    <item>
      <title>Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-presents-strong-data-showing-topical-vt-1908-is-an-effective-treatment-for-uveitis-opening-up-a-dollar3b-addressable-market-opportunity</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-presents-strong-data-showing-topical-vt-1908-is-an-effective-treatment-for-uveitis-opening-up-a-dollar3b-addressable-market-opportunity</guid>
      <pubDate>Wed, 17 Sep 2025 11:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., September 17, 2025--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1).</description>
    </item>
    <item>
      <title>Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-strengthens-leadership-team-with-industry-veterans-as-it-plans-pivotal-trial-studies</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-strengthens-leadership-team-with-industry-veterans-as-it-plans-pivotal-trial-studies</guid>
      <pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
      <description>Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (NASDAQ: HIND), a</description>
    </item>
    <item>
      <title>Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-announces-positive-interim-data-from-phase-2-study-of-vt-1953-in-malignant-fungating-wounds-mfw-and-provides-update-on-mfw-market-opportunity</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-holdings-announces-positive-interim-data-from-phase-2-study-of-vt-1953-in-malignant-fungating-wounds-mfw-and-provides-update-on-mfw-market-opportunity</guid>
      <pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
      <description>VT-1953 continues to significantly improve the primary endpoint Co-founder Dr. Shiladitya Sengupta to discuss over a live video conference VT-1953 treatment</description>
    </item>
    <item>
      <title>Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-signs-mou-with-embryyo-indias-leading-medical-device-innovation-studio</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-signs-mou-with-embryyo-indias-leading-medical-device-innovation-studio</guid>
      <pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
      <description>Vyome seeks to access multi-billion-dollar AI-enabled medical device market CAMBRIDGE, Mass. &amp; PUNE, India--(BUSINESS WIRE)-- Vyome Holdings, Inc. (Nasdaq:</description>
    </item>
    <item>
      <title>Vyome Announces Strategic Review of Livechain (OTCID: LICH)</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-strategic-review-of-livechain-otcid-lich</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-strategic-review-of-livechain-otcid-lich</guid>
      <pubDate>Mon, 18 Aug 2025 04:00:00 GMT</pubDate>
      <description>Vyome owns 70% of Livechain; Board focused on value creation CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND), a</description>
    </item>
    <item>
      <title>Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-to-mark-first-day-of-trading-as-hind-with-nasdaq-opening-bell</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-to-mark-first-day-of-trading-as-hind-with-nasdaq-opening-bell</guid>
      <pubDate>Fri, 15 Aug 2025 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., August 15, 2025--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, will be ringing the Nasdaq Opening Bell today in honor of its first day of trading as &quot;HIND.&quot; The occasion will also mark India’s 79th Independence Day.</description>
    </item>
    <item>
      <title>Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-closes-merger-transaction-will-trade-on-nasdaq-as-hind-tomorrow</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-closes-merger-transaction-will-trade-on-nasdaq-as-hind-tomorrow</guid>
      <pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases</description>
    </item>
    <item>
      <title>Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-nasdaq-approval-of-merger-with-reshape-lifesciences-set-to-begin-trading-as-hind</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-nasdaq-approval-of-merger-with-reshape-lifesciences-set-to-begin-trading-as-hind</guid>
      <pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
      <description>Effective as of Commencement of Trading on August 15, 2025 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Therapeutics, Inc., a clinical-stage healthcare company</description>
    </item>
    <item>
      <title>Vyome Announces New Board of Directors with Deep MIT and AI Ties</title>
      <link>https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-new-board-of-directors-with-deep-mit-and-ai-ties</link>
      <guid isPermaLink="true">https://6ix.com/company/vyome-holdings-inc/news/vyome-announces-new-board-of-directors-with-deep-mit-and-ai-ties</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 CAMBRIDGE,</description>
    </item>
  </channel>
</rss>